TY - JOUR
T1 - Baff and rheumatic autoimmune disorders
T2 - Implications for disease management and therapy
AU - Bosello, S.
AU - Pers, J. O.
AU - Rochas, C.
AU - Devauchelle, V.
AU - De Santis, M.
AU - Daridon, C.
AU - Saraux, A.
AU - Ferraccioli, G. F.
AU - Youinou, P.
PY - 2007/1
Y1 - 2007/1
N2 - Interest in B-cells has been revived due to the description of new functions. Supporting a role for B-cells in the genesis of autoimmune diseases is the fact that the B-cell activating factor of the TNF ligand family (BAFF) is essential in their physiology. However, in each disease, this is restricted to a subgroup of patients. Based on experiments in mice, and validated in humans, this new cytokine has been highlighted. Excessive production of BAFF alters immune tolerance by rescuing self-binding B-cells. Overexpression in mice leads to autoimmune manifestation, and BAFF levels are elevated in the serum of autoimmune patients. Similar abnormalities occur in chronic lymphocytic leukemia. Recent works suggest that antagonizing the protein (or competing for its receptors) is relevant to the treatment. Advances in our understanding of the BAFF system offers the opportunity to improve our therapeutic approach.
AB - Interest in B-cells has been revived due to the description of new functions. Supporting a role for B-cells in the genesis of autoimmune diseases is the fact that the B-cell activating factor of the TNF ligand family (BAFF) is essential in their physiology. However, in each disease, this is restricted to a subgroup of patients. Based on experiments in mice, and validated in humans, this new cytokine has been highlighted. Excessive production of BAFF alters immune tolerance by rescuing self-binding B-cells. Overexpression in mice leads to autoimmune manifestation, and BAFF levels are elevated in the serum of autoimmune patients. Similar abnormalities occur in chronic lymphocytic leukemia. Recent works suggest that antagonizing the protein (or competing for its receptors) is relevant to the treatment. Advances in our understanding of the BAFF system offers the opportunity to improve our therapeutic approach.
KW - Autoimmunity
KW - B-cell activating factor
KW - B-lymphocyte
KW - Rheumatoid arthritis
KW - Sjögren's syndrome
KW - Systemic lupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=33947729198&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33947729198&partnerID=8YFLogxK
M3 - Article
C2 - 17346422
AN - SCOPUS:33947729198
VL - 20
SP - 1
EP - 8
JO - International Journal of Immunopathology and Pharmacology
JF - International Journal of Immunopathology and Pharmacology
SN - 0394-6320
IS - 1
ER -